Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juliet E Wolford

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Expert Opinion on Drug Discovery|February 22, 2018
Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancerJuliet E Wolford, Krishnansu S Tewari
Future Oncology (London, England)|June 4, 2015
US FDA oncology drug approvals in 2014Juliet E Wolford, Krishnansu S Tewari
Journal of Gynecologic Oncology|August 1, 2017
Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical OncologyJuliet E Wolford, Krishnansu S Tewari
Current Oncology Reports|March 29, 2022
Integrating Precision Medicine into the Contemporary Management of Gynecologic CancersJuliet E Wolford, Erin Ferrigni, Daniel Margul, et al.
Expert Review of Molecular Diagnostics|February 8, 2020
A profile on the FoundationFocus CDxBRCA testsLindsey Ford, Juliet E Wolford, Sandra M Brown, et al.
Current Opinion in Obstetrics & Gynecology|December 14, 2019
Endometrial cancer in the morbidly obese: a reviewMarisa C Liu, Austin B Gardner, Juliet E Wolford, et al.
Gynecologic Oncology|March 17, 2020
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinomaJuliet E Wolford, Jiaru Bai, Kathleen N Moore, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Opinion on Drug Discovery|February 22, 2018
Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancerJuliet E Wolford, Krishnansu S Tewari
Future Oncology (London, England)|June 4, 2015
US FDA oncology drug approvals in 2014Juliet E Wolford, Krishnansu S Tewari
Journal of Gynecologic Oncology|August 1, 2017
Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical OncologyJuliet E Wolford, Krishnansu S Tewari
Current Oncology Reports|March 29, 2022
Integrating Precision Medicine into the Contemporary Management of Gynecologic CancersJuliet E Wolford, Erin Ferrigni, Daniel Margul, et al.
Expert Review of Molecular Diagnostics|February 8, 2020
A profile on the FoundationFocus CDxBRCA testsLindsey Ford, Juliet E Wolford, Sandra M Brown, et al.
Current Opinion in Obstetrics & Gynecology|December 14, 2019
Endometrial cancer in the morbidly obese: a reviewMarisa C Liu, Austin B Gardner, Juliet E Wolford, et al.
Gynecologic Oncology|March 17, 2020
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinomaJuliet E Wolford, Jiaru Bai, Kathleen N Moore, et al.
Pageof 1